Treating Acute Leukemias
in Latin America
Bridging Science and Practice: From Newest Clinical Approaches to Real-World Clinical Cases
Overview
This 2-day virtual program offers a comprehensive overview of the latest clinical updates and novel treatment strategies for acute leukemia, presented by experts. Attendees will have the opportunity to gain knowledge on optimal treatment of leukemia patients, join patient case-based discussions, and interact with experts.
Date and Location
October 19–20, 2023, Webinar
Co-Chairs
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Naval Daver, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty
Roberta Demichelis, MD
Instituto Nacional de Ciencias Médicas y Nutrición Salvador, Zubirán,
Mexico
Wellington Silva, MD
Hospital Regional de São José,
Brazil
Phillip Scheinberg, MD, PhD
Hospital de São José, Beneficencia Portuguesa de São Paulo,
Brazil
Josep-Maria Ribera, MD, PhD
Catalan Institute of Oncology,
University Hospital Germans Trias i Pujol,
Spain
|
Agenda |
This 2-day interactive virtual meeting with global experts will focus on the treatment of patients with acute leukemia in various countries within the LATAM region. Day 1: Follow interactive presentations and case-based discussions on the latest updates for ALL and AML prognosis and management, including the role of MRD, risk stratification, and long-term safety considerations, and engage with the faculty in panel discussions on optimal treatment, patient access, and regional challenges across the LATAM region. Day 2: Join to learn more about current approaches for relapsed ALL and AML, considerations for AYA ALL management (including case-based discussions), and the evolving role of transplantation, and interact with faculty during a panel discussion on how first-line therapy influences subsequent treatment. |
Day 1: Plenary Sessions
Thursday, October 19, 2023
4.00 PM – 7.00 PM (UTC -6) Mexico City
5.00 PM – 8.00 PM (UTC -5) Houston/Bogota
7.00 PM – 10.00 PM (UTC -3) Brasilia/Buenos Aires
| Time (UTC-3) | Topic | Presenter |
| 7.00 PM – 7.10 PM | Welcome and meeting overview | Elias Jabbour |
| 7.10 PM – 7.25 PM | Review of prognostic value of MRD in ALL and AML | Phillip Scheinberg |
| 7.25 PM – 7.40 PM | Latest achievements and developments in ALL and AML | Elias Jabbour |
| 7.40 PM – 7.50 PM | Best practices for first-line treatment in ALL | Josep-Maria Ribera |
| 7.50 PM – 8.05 PM | AYA ALL patients: What is the current treatment approach for this diverse patient population? Special considerations for adolescents and young adults and how we can use this experience in adult patients | Wellington Silva |
| 8.05 PM – 8.35 PM |
ALL case-based panel discussion
|
Roberta Demichelis (local cases), Elias Jabbour, and all faculty |
| 8.35 PM – 8.45 PM | Break | |
| 8.45 PM – 9.10 PM | Genetic characterization and risk stratification of AML; role of FLT3 and IDH in AML and Special considerations for young and fit patients | Naval Daver |
| 9.10 PM – 9.25 PM | Therapeutic approaches in high-risk and frail AML patients | Phillip Scheinberg |
| 9.25 PM – 9.50 PM | Panel discussion: Open questions in ALL and AML – regional challenges (transplant, CAR T, studies, and other) | Elias Jabbour and all faculty (present 2–3 slides as trigger) |
| 9.50 PM – 10.00 PM | Session close) | Elias Jabbour and all faculty (present 2–3 slides as trigger)Elias Jabbour |
Day 2: Plenary Sessions
Friday, October 20, 2023
4.00 PM – 7.00 PM (UTC -6) Mexico City
5.00 PM – 8.00 PM (UTC -5) Houston/Bogota
7.00 PM – 10.00 PM (UTC -3) Brasilia/Buenos Aires
| Time (UTC-3) | Topic | Presenter |
| 7.00 PM – 7.10 PM | Welcome to Day 2 | Naval Daver |
| 7.10 PM – 7.30 PM | Current treatment options for relapsed ALL in adult and elderly patients | Elias Jabbour |
| 7.30 PM – 7.50 PM | Current treatment options for relapsed AML in adult and elderly patients | Naval Daver |
| 7.50 PM – 8.20 PM |
AML case-based panel discussion
|
Roberta Demichelis (local cases), Naval Daver, and all faculty |
| 8.20 PM – 8.30 PM | Break | |
| 8.30 PM – 8.50 PM | Long-term safety considerations for leukemias | Josep-Maria Ribera |
| 8.50 PM – 9.10 PM | Current and future role of transplantation in acute leukemias in Latin America | Wellington Silva |
| 9.10 PM – 9.50 PM |
Panel discussion: How treatment in first line influences further approaches in ALL and AML
|
Elias Jabbour, Naval Daver, and all faculty |
| 9.50 PM – 10.00 PM | Session close | Elias Jabbour |
